SCHEDULE: Deep Track Capital Boosts Ocular Therapeutix Stake to 6.18%

Deep Track Capital, along with its affiliates, has disclosed a 6.18% beneficial ownership stake in Ocular Therapeutix, Inc. as of September 30, 2025.

Summary

• Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd., and David Kroin collectively reported beneficial ownership of 13,095,855 shares of Ocular Therapeutix, Inc. common stock.
• This aggregate amount represents 6.18% of the company's outstanding common stock.
• The ownership calculation is based on 211,998,125 shares, which includes 210,834,407 common shares outstanding as of September 30, 2025, and 1,163,718 common shares convertible from Pre-Funded Warrants.
• The Pre-Funded Warrants are subject to a 9.99% maximum percentage exercise limitation, preventing the holder from beneficially owning in excess of 9.99% of the common stock outstanding after exercise.
• The reporting persons hold shared voting and dispositive power over all 13,095,855 shares, with no sole voting or dispositive power.
• The filing was made under Rule 13d-1(b), with Deep Track Capital, LP classified as an investment adviser and David Kroin as a control person.

Sentiment

Score: 7

Explanation: The disclosure of a significant beneficial ownership stake by a specialized institutional investor like Deep Track Capital is generally viewed as a positive signal, indicating confidence in the company's value or future potential. While not a direct performance report, it suggests a favorable institutional perspective.

Positives

• A significant institutional investment firm, Deep Track Capital, has taken a substantial 6.18% stake in Ocular Therapeutix, Inc., signaling potential confidence in the company's prospects.
• The investment aligns with Deep Track Capital's specialization in the biotechnology sector.

Risks

• The filing certifies that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer, mitigating immediate activist investor concerns.

Future Outlook

NA

Industry Context

Deep Track Capital is an investment firm specializing in the biotechnology sector. Their significant stake in Ocular Therapeutix, Inc. indicates a strategic investment within their core industry focus, potentially reflecting a positive outlook on the company's position or future developments within the broader biotechnology landscape.

Stakeholder Impact

• Shareholders may view this as a positive indicator of institutional confidence in Ocular Therapeutix, Inc., potentially influencing market sentiment positively.
• The presence of a significant institutional investor could lead to increased scrutiny or engagement with company management, though the filing explicitly states no intent to influence control.

Key Dates

Recommendation

The disclosure of a significant 6.18% stake by Deep Track Capital, a specialized biotechnology investment firm, suggests institutional confidence in Ocular Therapeutix, Inc. While this filing does not provide operational or financial performance data, such a substantial investment by a sophisticated entity can be interpreted as a positive signal for the company's long-term prospects. For existing investors, this reinforces a 'hold' position, encouraging continued monitoring of the company's developments. For potential investors, it warrants a closer look into Ocular Therapeutix, Inc. as a potentially undervalued or promising asset, given the backing of a focused institutional player.

Keywords

Ocular Therapeutix, Deep Track Capital, Beneficial Ownership, Schedule 13G, Common Stock, Biotechnology, Institutional Investor, Investment Adviser, Warrants